These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 27989591)
1. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Kendall EA; Fojo AT; Dowdy DW Lancet Respir Med; 2017 Mar; 5(3):191-199. PubMed ID: 27989591 [TBL] [Abstract][Full Text] [Related]
2. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan. Trauer JM; Achar J; Parpieva N; Khamraev A; Denholm JT; Falzon D; Jaramillo E; Mesic A; du Cros P; McBryde ES BMC Med; 2016 Nov; 14(1):187. PubMed ID: 27855693 [TBL] [Abstract][Full Text] [Related]
3. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. Kendall EA; Azman AS; Cobelens FG; Dowdy DW PLoS One; 2017; 12(3):e0172748. PubMed ID: 28273116 [TBL] [Abstract][Full Text] [Related]
4. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of treating multidrug-resistant tuberculosis. Resch SC; Salomon JA; Murray M; Weinstein MC PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403 [TBL] [Abstract][Full Text] [Related]
6. Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach. Han WM; Mahikul W; Pouplin T; Lawpoolsri S; White LJ; Pan-Ngum W PLoS One; 2021; 16(3):e0248846. PubMed ID: 33770104 [TBL] [Abstract][Full Text] [Related]
7. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Kendall EA; Fofana MO; Dowdy DW Lancet Respir Med; 2015 Dec; 3(12):963-72. PubMed ID: 26597127 [TBL] [Abstract][Full Text] [Related]
8. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bastian I; Rigouts L; Van Deun A; Portaels F Bull World Health Organ; 2000; 78(2):238-51. PubMed ID: 10743297 [TBL] [Abstract][Full Text] [Related]
9. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Chee CBE; KhinMar KW; Sng LH; Jureen R; Cutter J; Lee VJM; Wang YT Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28798092 [No Abstract] [Full Text] [Related]
11. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients. Pawar UM; Kundnani V; Agashe V; Nene A; Nene A Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244 [TBL] [Abstract][Full Text] [Related]
12. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Weltman AC; Rose DN Arch Intern Med; 1994 Oct; 154(19):2161-7. PubMed ID: 7944836 [TBL] [Abstract][Full Text] [Related]
14. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Li R; Ruan Y; Sun Q; Wang X; Chen M; Zhang H; Zhao Y; Zhao J; Chen C; Xu C; Su W; Pang Y; Cheng J; Chi J; Wang Q; Fu Y; Huan S; Wang L; Wang Y; Chin DP Lancet Glob Health; 2015 Apr; 3(4):e217-28. PubMed ID: 25794675 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Van Deun A; Salim AH; Rigouts L; Rahman M; Fissette K; Portaels F Int J Tuberc Lung Dis; 2001 Apr; 5(4):329-38. PubMed ID: 11334251 [TBL] [Abstract][Full Text] [Related]
16. Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis. Yew WW Chemotherapy; 1999; 45 Suppl 2():26-33. PubMed ID: 10449895 [TBL] [Abstract][Full Text] [Related]
17. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Gupta R; Espinal MA; Raviglione MC Int J Tuberc Lung Dis; 2000 Nov; 4(11):1089-91. PubMed ID: 11092726 [No Abstract] [Full Text] [Related]
18. Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Balabanova Y; Fiebig L; Ignatyeva O; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F Thorax; 2017 Sep; 72(9):850-852. PubMed ID: 28209653 [TBL] [Abstract][Full Text] [Related]
19. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Yew WW Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001 [TBL] [Abstract][Full Text] [Related]
20. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]